Stallergenes S.A.

Over the last few decades, respiratory allergic diseases have become considerably widespread in the population. They have reached record levels in western countries, where it is estimated that about one in four people have clinical symptoms of allergy. About 90 million Europeans and 65 million Americans are affected by allergic respiratory diseases.

Among the therapeutic approaches offered to treat allergies, there is our specialty: desensitisation (or specific immunotherapy) is the only treatment that makes it possible to redirect the immune system by treating the cause of the disease itself.

A forerunner and leader in desensitisation therapies, possessing 45 years of experience, STALLERGENES treated nearly 500 000 patients in 2006. Present in more than 40 countries, our company is dedicated to the research, development; manufacturing and distribution of allergen extract products for the primary treatment of allergic rhinitis and asthma.

Over the last couple of years, STALLERGENES has undergone strong growth and is reinforcing its position in many markets.

Thanks to this growth, STALLERGENES commits to offering doctors and patients therapies that are all the more innovative. STALLERGENES has intensified its research and development efforts. The R&D budget in 2007 corresponds to over 15% of sales.